Currently several members of International Longevity Alliance (ILA) are preparing chapters for the forthcoming volume on “Healthy Longevity: Policies and Practices” that will be published in the Springer Nature book series “Healthy Ageing and Longevity” (the volume is edited Dr. Ilia Stambler)
https://www.springer.com/series/13277
The book is expected to be completed in 2025, and published in the end of 2025-beginning of 2026.
Generally, the book will relate to the analysis and development of policies for the advancement of healthy longevity research, development, education and implementation. It is expected to make a good contribution for the longevity cause, as it would help clarify (to the general public as well as to the longevity advocates) what it is exactly that the longevity movement advocates for. It will help develop longevity policy and advocacy research, help bring the subject of “Healthy Longevity: Policies and Practices” into university libraries and classroom discussions, as well as create an authoritative reference source for longevity research advocacy and policy to address decision makers and general public.
Here is the book description. Looking forward to this publication!
This multi-chapter review book will elaborate on the current practices and policies in research, development, dissemination and application of therapies intended to ameliorate degenerative aging processes and extend healthy and productive longevity. The main subjects relate to the connection of longevity science, technology and society, including R&D and educational policies and governance, regulation, accessibility of emerging therapies, biological and medical ethics, public perception, support and involvement in the longevity field. The book will examine the current practical implementation of the policies for longevity therapy research, development and application, including the bottlenecks of implementation and their mitigation, as well as incentives for the beneficial development of the longevity field. The book will examine a wide variety of methodological and policy issues involved in research, development and application of therapies intended to ameliorate aging processes and extend healthy longevity. These include clarification of basic terms and definitions in relation to anti-aging and longevity therapies. It will examine definitions and evaluation criteria of clinical benefits of such therapies, including biological, functional and clinical endpoints and study design. It will consider the existing and desirable regulatory frameworks for developing longevity therapies. The book will examine methodological issues of geroscience research, and their possible solutions and mitigations, including minimization of confounding factors of geroscience research, relevance of research to human subjects, in particular older persons, long-term and integrated multidisciplinary studies. The book will consider qualification and quantification criteria of longevity studies, maximizing the informative, predictive and integrative value of longevity studies, including questions of data quality, openness and sharing. Finally, the book will examine the practical benefits of longevity studies and emerging longevity therapies for human subjects, including questions of safety and efficacy, standardization, avoiding selection and other biases, cost-effectiveness, affordability, and universal distribution. This volume, written by world leading experts working in the diverse aspects of the longevity field, will contribute to analyzing methodological and policy challenges and devising biomedical and societal solutions to improve healthy longevity for the population.